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Purpose. To evaluate the contribution of the ocular risk factors in the conversion of the fellow eye of patients with unilateral
exudative AMD, using a novel semiautomated grading system.Materials and Methods. Single-center, retrospective study including
89 consecutive patients with unilateral exudative AMD and ≥3 years of followup. Baseline color fundus photographs were graded
using an innovative grading software, RetmarkerAMD (Critical Health SA). Results. The follow-up period was 60.9 ± 31.3months.
The occurrence of CNVwas confirmed in 42 eyes (47.2%).The cumulative incidence of CNVwas 23.6% at 2 years, 33.7% at 3 years,
39.3% at 5 years, and 47.2% at 10 years, with a mean annual incidence of 12.0% (95%CI = 0.088–0.162). The absolute number of
drusen in the central 1000 and 3000 𝜇m (𝑃 < 0.05) and the absolute number of drusen ≥125 𝜇m in the central 3000 and 6000 𝜇m
(𝑃 < 0.05) proved to be significant risk factors for CNV. Conclusion. The use of quantitative variables in the determination of the
OR of developing CNV allowed the establishment of significant risk factors for neovascularization. The long follow-up period and
the innovative methodology reinforce the value of our results. This trial is registered with ClinicalTrials.gov NCT00801541.
1. Introduction
Age-relatedmacular degeneration (AMD) poses a substantial
public health problem worldwide [1–4]. The exudative form
is the leading cause of irreversible vision loss in subjects over
65 years of age living in economically developed countries
and accounts for >80% of cases of legal blindness associated
with the disease [5–7]. Risk estimation is crucial in order to
provide adequate patientmonitoring. Fellow eyes of individu-
als with unilateral exudative AMD should receive the utmost
attention since they are known to have an increased risk of
developing choroidal neovascularization (CNV) [4, 5, 8, 9].
The role of retinal imaging in AMD has long been
recognized. Several studies have concluded that digital imag-
ing is reliable for the purpose of grading AMD, both in
clinical practice and in clinical trials [10, 11].The International
Classification and Grading System [12] was created to pro-
vide a uniform and internationally accepted nomenclature
and grading system for the disease, based on color fundus
photography’s morphological findings. Implementation of
this system in large cohort epidemiological studies helped
establishing significant determinants for the development of
wet AMD [4, 13–15] and led to the creation of a fundus
photography-based severity scale by the AREDS group [16].
This simplified scale uses a point scoring systemand estimates
the 5-year risk of developing advanced AMD. The three
variables included are the presence/absence of (1) large
drusen (≥125 𝜇m), (2) pigmentary changes (hypo- or hyper-
pigmentation) and (3) neovascular AMD.The major goals of
risk estimation are to provide baseline risk categories, to allow
tracking of progression, and to define surrogate outcomes for
progression to the advanced forms of the disease [17].
The importance of drusen characteristics (such as the area
and number of drusen) in the development of wet AMD has
been highlighted by several studies [13–15, 18].When grading
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is performed with conventional reading center techniques,
the depiction of these variables is categorical in nature. Taking
the number of drusen as an example, a simplified categorical
assessment, as provided by the International Classification
and Grading System for AMD [12], would grade one image
having 0, 1–9, 10–19, or≥20 drusen. Statistical analysismodels
using continuous variables (such as the real number of drusen
or the real area of drusen) are generally more robust, hence
providing far more reliable results [19].
The advent of computer-assisted grading systems repre-
sents a significant advance in retinal imaging. Not only do
they make the grading process more efficient, but they also
deliver faster data analysis when compared to themore labor-
intensive conventional reading center methods [18, 20–22].
Using a novel semiautomated grading software capable
of categorical and continuous variable grouping (Retmark-
erAMD), this study aims to evaluate the contribution of the
ocular risk factors in the development of CNV in the fellow
eyes of patients with unilateral exudative AMD.
2. Material and Methods
The retrospective, single-center study included 89 consecu-
tive patients with unilateral exudative AMD. Patients with
neovascular AMD in one eye (the nonstudy eye) and early
age-related maculopathy in the fellow eye (study eye) were
enrolled. Inclusion criteria were (a) age ≥ 50 years; (b) any
race and either sex; (c) clinical diagnosis of wet AMD in one
eye (non-study eye), and the presence of the following char-
acteristics in the second eye (study eye): (1) ≥5 intermediate
drusen (≥63 and <125 𝜇m), ≥1 large soft drusen ≥ 125 𝜇m,
and/or confluent drusen, within the central 3,000𝜇m region,
and (2) with or without pigmentary changes; (d) ≥3 years of
followup after development of CNV in the non-study eye; and
(e) baseline color fundus pictures of the study eye at the time
of conversion of the non-study eye. Exclusion criteria were (a)
presence of other ophthalmologic diseases likely to jeopardize
the grading of the color fundus pictures; (b) non-AMD-
related CNV in the non-study eye; (c) clinical or fundoscopic
signs of myopic retinopathy or refractive power ≥8D; and (d)
evidence of past or present CNV in the study eye.
2.1. Grading Fundus Color Photography. Mydriatic color fun-
dus digital photographs taken at the time of conversion
of the non-study eye were used for grading. The pictures
were centered on the fovea, with a 30-degree field of view.
Grading took place at the Coimbra Ophthalmology Reading
Center (CORC) by graders certified by this institution. For
the certification process, an agreement between graders was
developed as generalized kappa-type statistics, with a kappa
value >0.61 required for approval [23].
Grading was performed using the RetmarkerAMD (Crit-
ical Health SA), a computer-assisted grading system that
follows the guidelines of the International Classification and
Grading System for AMD [12].The system does not automat-
ically detect lesions, but its components allow to (i) differ-
entiate graded from nongraded images; (ii) assess images in
full-screen view; (iii) draw free forms of all lesion types over
the images; (iv) draw preset circular objects of different color
codes and sizes (63 𝜇m, 125 𝜇m, 175 𝜇m, 250𝜇m, or 500𝜇m)
to represent drusen, hyperpigmentation, hypopigmentation,
geographic atrophy, and exudative lesions; (v) mark drusen
as confluent; (vi) zoom in/out the image or display an
image area with a higher/lower degree of magnification; (vii)
measure distances in the image and control red/blue/green
channels (RGB), brightness, and contrast; (viii) superimpose
a standard grid to identify eye subfields, and (ix) manually
enter patient data.
Each image is calibrated before any measurement is
performed.Theusermanually indicates the optic disc vertical
limits along with the center of the macula (fovea), as shown
in Figure 1(a). An optic disc with diameter of 1.5mm is used
as reference by the software to set up an overlaying reference
grid (diameter 6000𝜇m), where measurements take place.
The grid consists of 3 concentric circles and a right-angled
cross at 45∘ and 135∘ to the horizontal, which is adjusted
according to the previous calibration (Figure 1(b)). As per
the International Classification and Grading System [12], the
diameters of the central, inner, and outer circles are 1000,
3000, and 6000𝜇m, respectively.
The fundus signs allowed to be graded by this tool include
(a) number of drusen (total, <63𝜇m, ≥63 and <125 𝜇m,
and ≥125 𝜇m); (b) drusen type (hard, soft distinct, soft
indistinct, semisolid, serogranular, or crystalline); (c) total
area occupied by drusen (<1%, <10%, <25%, <50%, ≥50%, for
central, inner, and outer circles separately); (d) cumulative
real area occupied by drusen and area of each subfield;
(e) confluence of drusen (absent, <10%, <50%, ≥50%); (f)
hyperpigmentation and hypopigmentation (absent, <125 𝜇m,
<175 𝜇m, ≥175 𝜇m) of the retinal pigment epithelium; (g)
atrophic AMD; and (h) neovascular AMD.
Using this semi-automated grading system, the results are
displayed on screen in real time, and the final characterization
of soft distinct, indistinct, reticular, or crystalline drusen is
performed by the operator.
Preliminary results from comparative tests held at our
institution have shown that RetmarkerAMD is more effective
than 35mm film manual grading [20]. Aside from being
timesaving (overall 35% faster), the software has also proved
to be more accurate (overall 32% more lesions identified)
[Silva R., oral presentation, EURETINA 2010].
2.2. Statistical Analysis. Data were characterized with
descriptive statistics and explored with classification trees
using CRT algorithm. Differences between eyes that con-
verted and those who did not were assessed using the Pearson
𝜒
2 test and Fisher’s exact test for nominal variables and the
Student’s t-test andMann-WhitneyU test for scalar variables.
Cumulative hazards for conversion times were calculated.
Multivariate logistic regressions were used to calculate
the odds ratio, expressing the effects of all of the tested
explanatory factors for eye conversion in two models: (1)
considering only large drusen (≥125 𝜇m) and (2) considering
all drusen. The following parameters were considered in
the multivariate analysis: real number of drusen, real area
occupied by drusen, presence of hyperpigmentation, and age
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Figure 1: Print screens of real-time grading using RetmarkerAMD. (a) Calibration is achieved after manually identifying the fovea and
establishing optic disc diameter (blue dot and arrow, resp.). The software then generates a reference grid (b) that follows the International
Classification and Grading System for AMD [12]. (c) Both free forms and predefined circles (63𝜇m, 125 𝜇m, 175𝜇m, 250 𝜇m, and 500 𝜇m)
can be used for quantifying fundus features in digital color fundus photographs, including drusen, pigmentary changes, geographic atrophy,
or exudative lesions.
at diagnosis. Results with P values <0.05 were considered
statistically significant. Data were analyzed using STATA
software (StataCorp, College Station, TX, USA) Version 12.1
SE and SPSS 16.0 program (Statistical Package for Social
Sciences; SPSS Inc., Chicago, IL, USA).
3. Results
Eighty-nine subjects were enrolled in the study.The study eye
was the right eye in 47 individuals (52.8%) and the left eye
in 42 (47.2%) individuals. The patients were aged between 55
and 92 years (mean ± SD: 74.2 ± 6.86 years), with a slight
female predominance—58.4% (𝑛 = 52). The average age
at conversion of the study eye was 77.5 ± 6.16, years and
the time to conversion ranged between 12 and 113 months
(median 28.5; IQR 24–43). The follow-up period was 60.9 ±
31.3 months (median 37; IQR 36–74).
The occurrence of CNVwas confirmed in 42 (47.2%) eyes
during followup (Table 1). The progression of the cumulative
risk of conversion is shown in Figure 2.The incidence ofCNV,
calculated for the follow-up period, was 12.0%/year (95% CI
= 0.088–0.162).
Even though drusen were universally identified (𝑛 =
89), pigmentary changes were only found in a small group
of patients (𝑛 = 22). The variables initially tested to
determine the predictive value of conversion in exudative
AMD are shown in Table 2. In this first approach, we built
the univariate analysis system using categorical variables,
exported as such from the RetmarkerAMD software: number
of drusen (0, 1–9, 0–19, ≥20), area occupied by drusen (<1%
<10%, <25%, <50%, ≥50%), hypo- and hyperpigmentation
(absent, <63 𝜇m, ≥63𝜇m), and confluence of drusen (<10%,
<50%, ≥50%). Drusen area within the inner circle was the
only variable demonstrating a statistically significant different
distribution across the conversion group (𝑃 < 0.05).
In order to increase the robustness of the analysis, we used
continuous variables: the real (absolute) number and area
occupied by drusen (Table 3). We tested these variables for
the totality of drusen and for large drusen (≥125 𝜇m) only and
Table 1: Choroidal neovascularization: number or events, cumula-
tive incidence, and cumulative risk over the ten-year period of follow
up.
Time
(years)
CNV
occurrence
(n)
Cumulative
incidence
(%)
Cumulative risk
1 7 7.9 0.0787 (95% CI = 0.0375–0.1650)
2 14 23.6 0.2532 (95% CI = 0.1650–0.3885)
3 9 33.7 0.3889 (95% CI = 0.2713–0.5575)
5 5 39.3 0.5418 (95% CI = 0.3787–0.7750)
10 7 47.2 1.4674 (95% CI = 0.8547–2.5194)
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Figure 2: Cumulative hazard for conversion over the ten-year
followup period.
separately for the central 1000 𝜇m, 3000 𝜇m, and 6000𝜇m in
order to appraise the role of the location in the development
of neovascular events. Results are shown in Table 4. The
real number of drusen in the central 1000𝜇m was the only
variable with a statistically significant result (𝑃 < 0.05).
Multivariate logistic regressions were then conducted,
calculating the odds ratio (OR) for each covariate. The
parameters considered were real number of drusen, real
area of drusen, presence of pigmentary changes, and age
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Table 2: Univariate analysis to determine the predictive value of
conversion, using variables expressed in a categorical manner.
Variable Pearson 𝜒2 𝑃 value
Predominant type of drusen in
the central 6000 𝜇m — 0.697
Number of drusen — 0.535
Area covered by drusen in the
central 1000𝜇m — 0.805
Hyperpigmentation — 0.515
Hypopigmentation — 0.192
Number of drusen <63𝜇m — 0.566
Number of drusen ≥63𝜇m and
<125 𝜇m 6.5333 0.088
Number of drusen ≥125𝜇m — 0.848
Total area covered by drusen — 0.358
Total area covered by drusen in
the central 3000𝜇m — 0.024
Total area covered by drusen in
the central 6000 𝜇m — 0.470
Confluence of drusen — 0.738
Age-related macular
degeneration stage — 0.604
Table 3: Baseline morphologic drusen characteristics (number and
area) expressed as continuous variables.
Parameter 𝑛 Median Interquartilerange
Within central 1000𝜇m
Number of drusen ≥125𝜇m 89 1 0–4
Total number of drusen 89 6 1–13
Area occupied by drusen ≥125𝜇m 89 12 0–83
Total drusen area 89 44 7–113
Within central 3000𝜇m
Number of drusen ≥125𝜇m 89 26 1–47
Total number of drusen 89 83 33–143
Area occupied by drusen ≥125𝜇m 89 351 12–966
Total drusen area 89 689 127–1322
Within central 6000𝜇m
Number of drusen ≥125𝜇m 89 54 10–132
Total number of drusen 89 123 38–210
Area occupied by drusen ≥125𝜇m 89 742 93–1973
Total drusen area 89 1329 404–3180
at diagnosis. We defined two models: (1) considering large
drusen (≥125 𝜇m) only and (2) considering the totality of
drusen. The results obtained for the two models tested are
shown in Tables 5 and 6, respectively. In the first model, the
increase in number of drusen ≥ 125 𝜇m showed a positive
effect on the risk of conversion in the central 3000 and
6000𝜇mregions.The increase in the area occupied by drusen
≥ 125 𝜇m and the presence of hyperpigmentation resulted in
a decreased risk of developing CNV. In Model 2, increases in
Table 4: Univariate analysis to determine the predictive value of
conversion, using continuous variables.
Parameter Mann-Whitney 𝑈 test (𝑃 value)
Drusen ≥ 125 𝜇m All drusen
Central 1000𝜇m region
Real number of drusen 0.3232 0.0308
Real area of drusen 0.6274 0.3118
Central 3000 𝜇m region
Real number of drusen 0.0881 0.0844
Real area of drusen 0.4725 0.5126
Central 6000 𝜇m region
Real number of drusen 0.5287 0.3785
Real area of drusen 0.7529 0.6870
the total drusen number showed a positive effect on the risk
of conversion in the central 1000 and 3000 𝜇m regions. The
presence of hyperpigmentation showed to decrease the risk
of CNV in the central 3000 and 6000𝜇m regions.
4. Discussion
Prior studies (MPS [14, 15], AREDS [16]) comprising grading
and risk estimation based on morphological assessments of
baseline color fundus photography used manual grading and
had their grading data grouped according to the guidelines of
the International Classification andGrading System forAMD
[12]. As such, depiction of variables such as the number (0, 1–
9, 0–19, ≥20) and area occupied by drusen (<1% <10%, <25%,
<50%, ≥50%) was categorical in nature, which inevitably
produces some estimates that can be a source of bias.
Although still not widely used in clinical or research
settings, the development of semi-automated image analy-
sis systems can significantly reduce the time and expense
involved in manual grading. The use of innovative software
in digital color fundus photography grading is changing the
way reading centers work around the world, as it represents
a convenient and versatile way of imaging and grading
fundus changes. Friberg et al. [19] used a computer-based
algorithm to detect and characterize drusen on digitized
images and showed that quantitative detection of drusen can
be performed reproducibly and efficiently using this method
[19]. When compared to more labor intensive reading center
techniques, the results were similar but the algorithm showed
higher precision and accuracy [19].
RetmarkerAMD is a revolutionary platform with a user-
friendly interface built upon the International Classification
and Grading System for AMD’s guidelines [12]. The software
has already been validated for quantification of AMD features
[Sima˜o, S. et al., poster presentation, ARVO 2011] and is
currently being used in an ongoing epidemiologic study of
AMD in the Portuguese population with an estimated num-
ber of 4000 participants (NCT01298674). When compared
to manual grading, the software was more effective and less
time consuming (nearly 35% faster), allowing identification
of 32% more lesions and reducing human error [Silva R.,
ISRN Ophthalmology 5
Table 5: Model 1 of multivariate analysis: logistic regression with odds ratio (OR) estimates considering only large drusen (≥125𝜇m).
Parameter OR Standard error 𝑃 value 95% CI
Central 1000𝜇m region
Age 0.985 0.057 0.796 0.880–1.103
Drusen number (continuous) 1.297 0.195 0.083 0.966–1.740
Area occupied by drusen (continuous) 0.990 0.008 0.194 0.975–1.005
Pigmentation (yes/no) 0.148 0.183 0.123 0.013–1.673
Central 3000𝜇m region
Age 0.920 0.755 0.309 0.783–1.080
Drusen number (continuous) 1.091 0.033 0.004 1.028–1.158
Area occupied by drusen (continuous) 0.997 0.001 0.021 0.995–1.000
Pigmentation (yes/no) 0.018 0.031 0.019 0.001–0.512
Central 6000𝜇m region
Age 0.957 0.067 0.528 0.835–1.097
Drusen number (continuous) 1.028 0.013 0.030 1.003–1.054
Area occupied by drusen (continuous) 0.999 0.001 0.034 0.998–0.999
Pigmentation (yes/no) 0.036 0.053 0.024 0.002–0.649
Table 6: Model 2 of multivariate analysis: logistic regression with odds ratio (OR) estimates considering the totality of drusen.
Parameter OR Standard Error 𝑃 Value 95% CI
Central 1000𝜇m region
Age 1.006 0.040 0.871 0.931–1.088
Drusen number (continuous) 1.106 0.041 0.007 1.029–1.189
Area occupied by drusen (continuous) 0.996 0.003 0.200 0.990–1.002
Pigmentation (yes/no) 0.664 0.092 0.049 0.004–0.993
Central 3000𝜇m region
Age 0.949 0.071 0.480 0.820–1.098
Drusen number (continuous) 1.017 0.008 0.024 1.002–1.032
Area occupied by drusen (continuous) 0.999 0.001 0.205 0.998–1.001
Pigmentation (yes/no) 0.041 0.058 0.024 0.003–0.652
Central 6000𝜇m region
Age 0.962 0.068 0.580 0.837–1.105
Drusen number (continuous) 1.006 0.003 0.051 1.000–1.012
Area occupied by drusen (continuous) 0.995 0.000 0.134 0.999–1.000
Pigmentation (yes/no) 0.037 0.056 0.029 0.002–0.710
oral presentation, EURETINA 2010]. One must not forget,
however, that, even though the advantages of using computer-
assisted grading systems are many, it may also be a source
of bias. One example would be image calibration with the
generation of the overlaying grid based on a reference optic
disc with a diameter of 1.5mm. Although this estimation of
the optic disc diameter has been used in several studies, it
does not account for the few cases where anatomic variants of
the optic disc are present and may thus constitute a weakness
of the software.
RetmarkerAMD produces standardized and detailed
records in Excel that allows easy data mining and statistical
analysis. Variables can be grouped both in a categorical and
in a continuous manner. Since statistical models operating
with quantitative variables provide more reliable results [19],
we took advantage of this unique ability to explore the effect
of drusen characteristics in the conversion of the fellow
eye. Our study combines the advantages of this innovative
and validated semi-automated software with a long-term
followup of a cohort consisting purely of fellow eyes of
patients with unilateral AMD. With this approach we meant
to eliminate the most consistent risk factor for CNV [17, 18],
consequently enabling better understanding of the role of
drusen characteristics in the development of wet AMD.
When testing the variables in a categorical manner,
the total area occupied by drusen within the inner circle
(central 3000 𝜇m) was the only variable associated with the
development of CNV (𝑃 < 0.05). This finding is consistent
with the results of the AREDS group [16], where variables
were tested categorically, and drusen area appeared to be a
stronger and more consistent risk factor than the number
of drusen. Interestingly, however, when we used continuous
variables, namely, the real (absolute) number and area of
drusen, the influence of drusen area in the conversion lost its
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Table 7: Cumulative incidences of CNV on the fellow eyes of patients with unilateral exudative AMD between our and other studies.
Authors Followup 𝑛 Cumulative incidence (years)
(months) 2 3 4 5 10
Marques et al. (our study) 60.9 (36–148) 89 23.6% 33.7% 38.2% 39.3% 47.2%
Pauleikhoff et al. [24] 30.5 (6–80) 187 15.2% 26.1% 40.7% — —
Solomon et al. [25] 24–48 364 22% — 37% — —
MPS [14] 60 228 12% — 22% 42% —
MPS [15] 60 670 19% — 36% —
van Leeuwen et al. [26] 48–156 35 — — — 38.7% —
Uyama et al. [27] 47 (12–108) 170 5.6% — — 12.3% —
statistical significance, and the real number of drusen in the
central 1000𝜇m became the only variable correlated with the
development of exudative AMD in the fellow eye (𝑃 < 0.05).
In order to clarify the role of each determinant inde-
pendently, we conductedmultivariate logistic regressions and
calculated the odds ratio (OR) for each covariate. We found
that both the real number of (total) drusen (in the central
1000 and 3000 𝜇m) and the real number of (large) drusen ≥
125 𝜇m (in the central 3000 and 6000 𝜇m) were significant
risk factors for the occurrence of neovascular events (𝑃 <
0.05). However, the real area occupied by drusen ≥ 125 𝜇m
proved to be inversely correlated with the development of
CNV (𝑃 < 0.05).The AREDS group [16] stated that the num-
ber of large drusen (≥125 𝜇m) is closely related to the total
area of drusen and that the latter is a significant risk factor
for wet AMD. In a study conducted by Friberg et al. [21],
aiming to determine the relationship between the number of
drusen and drusen area, the authors found that the number
of large drusen does not correlate better with total drusen
area than drusen of other sizes, meaning that the number
of large drusen is not necessarily a good surrogate for total
drusen area. The same authors went further in another study
[18] where digital images of 949 eyes of patients included in
AREDS [16] and PTAMD [28] studies were retrospectively
evaluated by computerized methods, and the variables were
analyzed in a continuous manner. The author concluded
that total drusen area was not a consistent risk factor for
the development of CNV, and although the probability of
a neovascular event would increase with increasing drusen
area initially, the risk would then invert as a total drusen
area of ∼0.75mm2 was reached (∼60 large drusen) [18]. This
finding might justify our results. One possible explanation
would be that the eyes with higher drusen area develop
geographic atrophy (GA) instead of CNV. In CAPT [29], even
though there was no association between any of the drusen
measurements and the development of CNV, a correlation
was found between drusen area and the development of GA.
Like drusen size and area, pigmentary changes have
also been recognized previously as a risk factor for pro-
gression to wet AMD, both in individuals free of advanced
AMD bilaterally and in the fellow eye of subjects with
unilateral exudative AMD [15, 16, 29]. The presence of
hyperpigmentation is one of the risk factors associated with
CNV determined by the MPS group [15] and is also part
of the AREDS simplified severity scale [17]. In our study,
the presence of hyperpigmentation was inversely correlated
with the development of exudative AMD in both models of
multivariate analysis. This finding was unexpected. Friberg
et al. [18] found that this determinant was not a consistent
risk factor for an eye’s development of CNV, as the location of
the hyperpigmentation would influence its effect. In CAPT
[29], hyperpigmentation was associated both with CNV and
GA. As it represents degeneration of the retinal pigment
epithelium (RPE) and a relatively advanced stage of drusen
evolution, it is possible that either CNV or GA can follow its
appearance. Since we have not looked for the development of
GA in our cohort, we cannot correlate both. The difficulties
detecting hyperpigmentation and the relatively few patients
where we found it (𝑛 = 22)may have influenced our results.
The incidence of CNV in the fellow eyes of subjects with
unilateral exudative AMD is known to be high. In our study
there was a conversion rate of 12%/year (95% CI 0.088 to
0.162), a result consistent with other studies where it ranges
from 6 to 12%/year [15, 25, 30–32].
From the 89 patients enrolled, 42 (47.2%) developed CNV
during the follow-up period (an average of 5.1 years). This
number is higher than the ones reported by the extrafoveal
trial of the MPS group [14] (25.7% in a cohort of 128 eyes
with a 5-year followup) or the SST group [25] (26.9% in a
cohort of 364 eyes with a 4-year followup). The long-term
followup of our study (ranging from 36 to 148 months) may
justify some of this discrepancy.When comparing our results
with the AREDS subgroup with unilateral exudative AMD,
where the mean followup was 6.3 years, the disparity is less
prominent (38.9% in a cohort of 714 eyes).
The effect of systemic (smoking history, hypertension,
body mass index, and dietary habits) or genetic factors in
the conversion of the fellow eye was not accounted for in
our study. Although thesemight have had some impact, apart
from the smoking history, the influence of these determinants
in the development of exudative AMD is substantially less
important than the contribution of the ocular risk factors [13].
The cumulative incidence of CNV was 7.9% at the 1st
year, 23.6% at 2 years, 33.7% at 3 years, 39.3% at 5 years, and
47.2% at 10 years.These results are identical to those identified
in other large cohort studies [14, 15, 24–27], summarized in
Table 7. Opposing to the studies of Caucasian populations, it
is noteworthy to sign that, among Asians [27], the cumulative
incidence of CNV in the fellow eye is considerably lower.
In conclusion, RetmarkerAMDallowed the use of quanti-
tative variables in the determination of the OR of developing
CNV, thus establishing the real (absolute) number of drusen
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(in the central 1000 and 3000 𝜇m) and the real number of
drusen ≥ 125 𝜇m (in the central 3000 and 6000 𝜇m) as signifi-
cant risk factors for the conversion of the fellow eye.The long
follow-up period and the use of an innovative and validated
semi-automated grading software reinforce the value of our
results and support the influence of the ocular risk factors in
the progression of the fellow eye to exudative AMD.
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